Allarity Therapeutics, INC Form 4 insider transactions

Thomas Jensen, CEO of Allarity Therapeutics, Inc., acquired 200,000 restricted stock units on January 28, 2026, as part of the company's equity incentive plan.

Jesper Hoeiland, a Director at Allarity Therapeutics, Inc., reported the acquisition of 25,000 shares of common stock on January 7, 2026.

Director Gerald W. McLaughlin acquired 45,000 shares of Allarity Therapeutics, Inc. common stock via a restricted stock unit grant.

Jeremy R. Graff, President and Chief Development Officer of Allarity Therapeutics, was granted 133,333 restricted stock units.

Allarity Therapeutics CFO Jeffrey S. Ervin was granted 150,000 restricted stock units as part of the company's equity incentive plan.

Allarity Therapeutics, Inc. granted 133,333 restricted stock units to President and Chief Development Officer Jeremy R. Graff, vesting over three years.

Allarity Therapeutics' President and Chief Development Officer, Jeremy R. Graff, converted restricted stock units into common stock and subsequently sold a portion to cover tax obligations.

An amended SEC filing reveals a correction to the expiration and vesting dates of stock options granted to Allarity Therapeutics director Joseph Walter Vazzano.

Director Laura Benjamin of Allarity Therapeutics files an amended form to correct errors in the original filing regarding stock option vesting and expiration dates.

A director of Allarity Therapeutics, Gerald W. McLaughlin, amended a previous filing to correct the expiration and vesting dates of stock options granted to him.

Allarity Therapeutics' Chief Development Officer, Jeremy R. Graff, acquired 144,441 shares of common stock through the vesting of restricted stock units.

CFO of Allarity Therapeutics, Alexander Epshinsky, reports acquiring 29,496 shares of common stock on January 22, 2025.

Allarity Therapeutics CEO Thomas Jensen acquired 396,734 shares of common stock through the grant of restricted stock units.

Gerald W. McLaughlin, a director of Allarity Therapeutics, Inc., acquired 25,000 stock options on January 22, 2025.

Joseph Vazzano, a director at Allarity Therapeutics, acquired 25,000 stock options on January 22, 2025, which vest immediately.

Director Laura Benjamin acquired 25,000 stock options in Allarity Therapeutics on January 22, 2025.

Jeremy R. Graff, President and Chief Development Officer of Allarity Therapeutics, was granted 118,483 restricted stock units (RSUs) in connection with his appointment.